Listar DBCFI-Artículos, capítulos... por autor "a1e95307-b243-48b6-9395-cef2b5b69b3b"
Mostrando ítems 1-1 de 1
-
Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial
Roncero-Ramos, Irene; Gutiérrez Mariscal, Francisco Miguel; Gómez Delgado, Francisco; Villasanta-González, Alejandro; Torres‑Peña, J.D.; Cruz‐Ares, Silvia de la; Rangel Zúñiga, Oriol Alberto; Luque, Raúl M.; Ordovas, José M.; Delgado-Lista, Javier; Pérez-Martínez, Pablo; Camargo García, A.; Alcalá Díaz, Juan Francisco; López-Miranda, José (Elsevier, 2021)In order to assess whether previous hepatic IR (Hepatic-IR fasting) and beta-cell functionality could modulate type 2 diabetes remission and the need for starting glucose- lowering treatment, newly-diagnosed type 2 diabetes ...